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Introduction
Sweet syndrome (SS) is a rare autoinflamamtory neutro-
philic dermatosis, sometimes associated with hematologic
malignancies. We describe two cases of SS related to
hematologic diseases successfully treated with an interleu-
kin-1 (IL-1) receptor antagonist (Anakinra).
Case report
1- A 72-year-old man with diagnosis of Relapsing Poly-
chondritis and Myelodysplastic syndrome (MDS) was
referred for a 4-yr history of recurrent fever (37.5 to 39°C)
accompanied by sudden onset of cutaneous purple papules
on the extremities and hypodermic painful nodules on the
forehead and scalp. The patient suffered of autoimmune
atrophic gastritis and severe metasteroidal osteoporosis,
but also complained of recurrent auricular chondritis,
recurrent conjunctival inflammation, hearing loss, apho-
nia, and itching. Blood tests revealed high C-reactive pro-
tein (43.2 mg/l), pancytopenia, 1/160 titer of ANA, and
elevated beta2microglobulin (10.10 mg/ml). A host of
blood tests and broncho-alveolar lavage fluid were nega-
tive. Bone marrow (BM) biopsy confirmed MDS. Histopa-
tological evaluation of papules demonstrated neutrophilic
nodular dermatitis with karyorrhexis without vasculitis,
consistent with SS.
2- A 43-year-old man, with a 3-yr history of fever, peri-
odic bone pain, and presence of maculo-papular erythe-
matous skin lesions came to our observation. Histological
examination of skin lesions demonstrated a diffuse infil-
trate, consisting predominantly of mature neutrophils
located in the upper dermis, framed as SS. MRI of pelvis
and spine showed multiple sclerotic vertebral bone
lesions. BM biopsy did not detect tumor cells, but instead
identified inflammatory cells with intense sclerosis and
calcification. Diagnosis of Chronic Recurrent Multifocal
Osteomyellitis (CRMO) was established. Treatment with
etoricoxib, colchicine, corticosteroid was only partially
successful, whereas bisphosphonate and anti-TNF ther-
apy were completely uneffective.
In both these patients Anakinra was administered
(100 mg/day by daily subcutaneous injection), obtaining
the suppression of neutrophylic-mediated dermatologic
manifestations. In the first case we also observed fever
spike reduction, whereas in the second one there was the
complete remission of fever and bone pain.
Discussion
Pathogenesis of SS involves cytokines and chemokines, as
granulocyte-macrophage colony-stimulating factor and
interleukins (e.g, IL-1, IL-3, IL-6, and IL-8). The optimal
effect of Anakinra in these cases supports the major
contributing role of IL-1beta in the physio-pathogenetic
process of SS. The choice of alternative strategies, as anti-
IL1beta therapy, is feasible in the absence of detectable
infections to reduce adverse effects of long-term steroid




Published: 8 November 2013
References
1. Diamantino Fda E, Raimundo PM, Fidalgo AI: “Sweet’s Syndrome and
relapsing polychondritis signal myelodysplastic syndrome.”. Anais
Brasileiros de Dermatologia 2011, 86(4):173-177.
2. Calistru AM, Lisboa C, Azevedo F: “Paraneoplastic relapsing polychondritis
and Sweet syndrome coexisting in a patient with myelodysplasia.”.
Indian Journal of Dermatology, Venereology, and 3.Leprology 2011, 77(6):730.
3. Schilling F, Kessler S: Chronic recurrent multifocal osteomyelitis. Klin
Padiatr 2001, 213(5):271-6.
doi:10.1186/1546-0096-11-S1-A217
Cite this article as: Passaro et al.: P03-019 - Anakinra for sweet
syndrome treatment. Pediatric Rheumatology 2013 11(Suppl 1):A217.
Periodic Fever Research Center, Catholic University of Sacred Heart, Rome,
Italy
Passaro et al. Pediatric Rheumatology 2013, 11(Suppl 1):A217
http://www.ped-rheum.com/content/11/S1/A217
© 2013 Passaro et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
